The estimated Net Worth of John F. Paolini is at least $4.26 Milion dollars as of 1 September 2024. John Paolini owns over 66,538 units of Kiniksa Pharmaceuticals International Plc stock worth over $2,743,848 and over the last 6 years he sold KNSA stock worth over $0. In addition, he makes $1,517,240 as Senior Vice President and Chief Medical Officer at Kiniksa Pharmaceuticals International Plc.
Sign up
John Paolini KNSA stock SEC Form 4 insiders trading
John has made over 20 trades of the Kiniksa Pharmaceuticals International Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 66,538 units of KNSA stock worth $113,780 on 1 September 2024.
The largest trade he's ever made was exercising 66,538 units of Kiniksa Pharmaceuticals International Plc stock on 1 September 2024 worth over $113,780. On average, John trades about 10,095 units every 60 days since 2018. As of 1 September 2024 he still owns at least 112,730 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of John Paolini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Paolini biography
Dr. John F. Paolini M.D. Ph.D. serves as Senior Vice President and Chief Medical Officer of the Company. From August 2015 to August 2016, Dr. Paolini was Clinical Research Head of the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Inc., a pharmaceutical company ("Pfizer"), where he was responsible for bringing forward programs from preclinical through early clinical development and proof of concept. Prior to Pfizer, from August 2011 to July 2015, Dr. Paolini served as Chief Medical Officer of Cerenis Therapeutics, a biotechnology company focused on cardiovascular and metabolic diseases, where he was responsible for designing and executing clinical trials and regulatory strategy for a portfolio of products. Dr. Paolini holds an M.D. and a Ph.D. from Duke University School of Medicine, a B.A. and a B.S. from Tulane University, and completed his internship, residency and fellowship in Internal Medicine and Cardiology at Brigham and Women's Hospital, Boston.
What is the salary of John Paolini?
As the Senior Vice President and Chief Medical Officer of Kiniksa Pharmaceuticals International Plc, the total compensation of John Paolini at Kiniksa Pharmaceuticals International Plc is $1,517,240. There are 1 executives at Kiniksa Pharmaceuticals International Plc getting paid more, with Sanjiv Patel having the highest compensation of $4,765,670.
How old is John Paolini?
John Paolini is 55, he's been the Senior Vice President and Chief Medical Officer of Kiniksa Pharmaceuticals International Plc since 2019. There are 4 older and 12 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
What's John Paolini's mailing address?
John's mailing address filed with the SEC is , 23 OLD BOND STREET, THIRD FLOOR, LONDON, X0, W1S 4PZ.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... a Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of John Paolini stock trades at Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer